Catalyst Pharmaceuticals, Inc.
CPRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $492 | $398 | $214 | $141 |
| % Growth | 23.5% | 85.9% | 52.1% | – |
| Cost of Goods Sold | $69 | $52 | $34 | $22 |
| Gross Profit | $423 | $346 | $180 | $119 |
| % Margin | 86% | 86.9% | 83.9% | 84.5% |
| R&D Expenses | $13 | $93 | $20 | $17 |
| G&A Expenses | $168 | $47 | $54 | $23 |
| SG&A Expenses | $178 | $134 | $57 | $50 |
| Sales & Mktg Exp. | $10 | $87 | $3 | $26 |
| Other Operating Expenses | $37 | $33 | $1 | $0 |
| Operating Expenses | $228 | $259 | $78 | $67 |
| Operating Income | $195 | $87 | $102 | $52 |
| % Margin | 39.7% | 21.8% | 47.5% | 37.2% |
| Other Income/Exp. Net | $21 | $8 | $3 | $0 |
| Pre-Tax Income | $216 | $95 | $105 | $53 |
| Tax Expense | $52 | $23 | $22 | $13 |
| Net Income | $164 | $71 | $83 | $39 |
| % Margin | 33.3% | 17.9% | 38.8% | 28% |
| EPS | 1.38 | 0.67 | 0.8 | 0.38 |
| % Growth | 106% | -16.3% | 110.5% | – |
| EPS Diluted | 1.31 | 0.63 | 0.75 | 0.37 |
| Weighted Avg Shares Out | 118 | 106 | 103 | 103 |
| Weighted Avg Shares Out Dil | 125 | 114 | 111 | 108 |
| Supplemental Information | – | – | – | – |
| Interest Income | $16 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $38 | $33 | $1 | $0 |
| EBITDA | $233 | $120 | $103 | $53 |
| % Margin | 47.4% | 30.1% | 48.1% | 37.3% |